Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (Nasdaq: CDNA) announced it will report its first quarter 2021 financial results after market close on May 5, 2021. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for investors and analysts to discuss these results.
Interested parties can join the call by dialing 877-705-6003 for domestic or 201-493-6725 for international calls, referencing Conference ID: 13718586. A live webcast will also be available on CareDx's website.
CareDx, a leader in precision medicine, has announced the hosting of two symposia at the 2021 European Federation for Immunogenetics and Histocompatibility Conference (EFI) from April 21-23, 2021. The sessions will focus on pioneering data in HLA typing and post-transplant surveillance aimed at enhancing transplant patient care. With a total of eight abstracts and one oral presentation highlighting innovations in AlloSeq and QTYPE portfolios, the company aims to improve outcomes in organ transplantation and demonstrate its leadership in the field.
CareDx, Inc. (Nasdaq: CDNA) will exhibit at the 29th Annual UNOS Transplant Management Forum from April 19-22, 2021. On April 20, 2021, at 11:00 a.m. EDT, they will host a symposium titled “Providing Personalized Care for Every Step on the Transplant Journey.” Key topics include pre-transplant care with TX Connect, quality care with XynQAPI, and post-transplant care with AlloSure® dd-cfDNA. CareDx aims to provide integrated digital solutions to improve transplant patient care, highlighted by the recent acquisition of TX Connect.
CareDx, Inc. (CDNA) has launched a next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, aimed at supporting research in vaccine and drug development. This HLA typing service, powered by AlloSeq Tx17, offers superior gene content and efficient testing capabilities. The service has already been engaged by a top global pharmaceutical company. CareDx is focusing on expanding its global presence and enhancing support for drug development research, enhancing patient care worldwide.
CareDx (Nasdaq: CDNA) will participate in the National Kidney Foundation's 2021 Spring Clinical Meetings from April 6-10, 2021. The company will host a virtual exhibitor showcase titled “Next Generation Care for Kidney Transplant Patients” on April 6, featuring experts like Dr. Christopher Boshkos and Dr. Matthew Weir discussing AlloSure, a standard for kidney transplant surveillance. Additionally, CareDx will sponsor a CME program on April 8 focusing on acute rejection in kidney transplantation, showcasing leading medical professionals' insights.
CareDx, a precision medicine company, has recently announced key leadership appointments to bolster its growth and enhance the patient experience in transplant healthcare. Reg Seeto, President and CEO, emphasized a commitment to innovation and patient-focused integrated digital offerings. New hires include Titte R. Srinivas, M.D., as VP of Digital Development, and Steven Stone, Ph.D., as VP of KidneyCare. Promotions include Marica Grskovic, Ph.D., to VP of Cell Transplant Therapy, reflecting the company’s dedication to improving transplant patient care.
CareDx, Inc. (Nasdaq: CDNA) announced efforts to raise awareness for Vir Biotechnology’s COMET-ICE study, evaluating the monoclonal antibody VIR-7831 for early COVID-19 treatment in high-risk adults. The trial, which focuses on the immune-compromised transplant patient population, was halted for enrollment following recommendations from an Independent Data Monitoring Committee due to significant efficacy. CareDx aims to facilitate patient access to clinical trials, providing additional treatment options beyond vaccines for vulnerable transplant patients.
CareDx, a precision medicine company focused on transplant solutions, has acquired BFS Molecular, a software firm specializing in NGS-based patient testing. This acquisition strengthens CareDx's portfolio with advanced software and algorithm development capabilities for transplant surveillance products like AlloSeq cfDNA and AlloSeq HCT. Tim Hague, the former CEO of BFS Molecular, will join CareDx as Vice President of Global Lab Products Software, enhancing their bioinformatics expertise and presence in Europe. CareDx aims to improve the transplant patient journey through this strategic acquisition.
CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Ankur Dhingra as the new Chief Financial Officer, effective March 25, 2021. Dhingra brings over 25 years of finance and accounting experience, previously serving as Vice President of Investor Relations at Agilent Technologies. CEO Reg Seeto expressed confidence that Dhingra's expertise will enhance operational growth and financial performance at CareDx. The company focuses on precision medicine for transplant patients, offering various healthcare solutions throughout the entire transplant journey.
CareDx, Inc. (Nasdaq: CDNA) announced the acquisition of TX Services, LLC, including its TX Connect service, which adds 19,000 patient referrals for kidney transplants. This cloud-based service allows nephrologists and dialysis centers to streamline electronic referrals to transplant programs. The integration enhances CareDx's pre-transplant offerings, complementing existing services like XynManagement. CEO Reg Seeto highlighted that TX Connect aids in helping more kidney patients get on transplant waitlists, enhancing patient care through better communication and management across the healthcare continuum.